Jay Black Eli Lilly

Lilly Outlines For Investors How Its Innovation-Based Strate ...

Company remains committed to speeding innovation to patients and delivering value to customers.R&D pipeline boasts 70 potential medicines in clinical development, including 33 in Phases II and III.Company expects at least ten potential new medicines in Phase III by the end of 2011, representing opportunities to improve patient outcomes in core therapeutic areas such as neuroscience, diabetes and oncology, as well as new areas such as autoimmunity.Performance of currently marketed brands and three counter-cyclical growth engines of Japan, emerging markets and Elanco animal health expected to significantly counteract patent losses.Productivity gains continue to reduce the company's cost structure and create the capacity to fund R&D and business development, as well as to maintain the dividend.Consistent with previous guidance, financial outlook for 2011-2014 predicts at least $20 billion of revenue, $3 billion of net income and $4 billion of operating cash flow annually, with a return to growth after 2014 fueled by new product launches.At its meeting today with the investment community aptly entitled "Bridging to the Future," Eli Lilly and Company (NYSE: LLY) highlighted how its transformation efforts and innovation-based strategy will enable it to overcome upcoming patent expirations and deliver the next generation of promising medicines to patients. The company's senior management detailed the progress being made in its scientific labs and across Lilly's five business areas to increase productivity and accelerate the flow of potential new medicines from its robust development pipeline. The company also reaffirmed its mid-term financial outlook. "At Lilly, our future relies upon our ability to successfully discover and develop innovative medicines that address unmet patient needs," said John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer. "We're pursuing an R&D-based strategy in full knowledge that the bar for innovative medicines has never been higher and that our industry faces many challenges. Despite these challenges, global demographic and economic trends make a compelling case for innovative medicines. As people around the world live longer and global incomes rise, the demand for innovative medicines will continue to grow. "As a company, we are well-positioned to meet that demand.

The Pharmaceutical era

Report of proceedings of the Illinois Pharmaceutical Association at the annual meeting

Practical druggist and pharmaceutical review of reviews

Directory of Corporate Counsel 2011-2012 (2 Volumes)

Proceedings of the Indiana Academy of Science